R J T Mocking1, C M Pellikaan2, A Lok3, J Assies2, H G Ruhé4, M W Koeter2, I Visser2, C L Bockting5, M Olff6, A H Schene7. 1. Program for Mood disorders, Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands. Electronic address: R.J.Mocking@amc.uva.nl. 2. Program for Mood disorders, Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands. 3. Program for Mood disorders, Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands; Arq Psychotrauma Expert Group, Diemen, The Netherlands. 4. Program for Mood disorders, Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands; University Medical Center Groningen, Program for Mood and Anxiety Disorders, Department of Psychiatry, The Netherlands. 5. Department of Clinical Psychology, University of Groningen, The Netherlands; Department of Clinical and Health Psychology, Utrecht University, The Netherlands. 6. Arq Psychotrauma Expert Group, Diemen, The Netherlands; Center for Psychological Trauma, Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands. 7. Program for Mood disorders, Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands; Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands; Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, The Netherlands.
Abstract
BACKGROUND:Major depressive disorder (MDD) has been associated with low dehydroepiandrosterone-sulphate (DHEAS), - particularly relative to high cortisol - although conflicting findings exist. Moreover, it is unclear whether low DHEAS is only present during the depressive state, or manifests as a trait that may reflect vulnerability for recurrence. Therefore, we longitudinally tested whether low DHEAS and high cortisol/DHEAS-ratio in recurrent MDD (I) reflects a trait, and/or (II) varies with depressive state. In addition, we tested associations with (III) previous MDD-episodes, (IV) prospective recurrence, and (V) effects of cognitive therapy. METHODS: At study-entry, we cross-sectionally compared morning and evening salivary DHEAS and molar cortisol/DHEAS-ratio of 187 remitted recurrent MDD-patients with 72 matched controls. Subsequently, patients participated in an 8-week randomized controlled cognitive therapy trial. We repeated salivary measures after 3 months and 2 years. We measured clinical symptoms during a 10-year follow-up. RESULTS: Remitted patients showed steeper diurnal DHEAS-decline (p<.005) and a flatter diurnal profile of cortisol/DHEAS-ratio (p<.001) than controls. We found no state-effect in DHEAS or cortisol/DHEAS-ratio throughout follow-up and no association with number of previous episodes. Higher morning cortisol/DHEAS-ratio predicted shorter time till recurrence over the 10-year follow-up in interaction with the effects of cognitive therapy (p<.05). Finally, cognitive therapy did not influence DHEAS or cortisol/DHEAS-ratio. CONCLUSIONS: Diurnal profiles of DHEAS and cortisol/DHEAS-ratio remain equally altered in between depressive episodes, and may predict future recurrence. This suggests they represent an endophenotypic vulnerability trait rather than a state-effect, which provides a new road to understand recurrent depression and its prevention. TRIAL REGISTRATION: www.isrctn.com/ISRCTN68246470.
RCT Entities:
BACKGROUND: Major depressive disorder (MDD) has been associated with low dehydroepiandrosterone-sulphate (DHEAS), - particularly relative to high cortisol - although conflicting findings exist. Moreover, it is unclear whether low DHEAS is only present during the depressive state, or manifests as a trait that may reflect vulnerability for recurrence. Therefore, we longitudinally tested whether low DHEAS and high cortisol/DHEAS-ratio in recurrent MDD (I) reflects a trait, and/or (II) varies with depressive state. In addition, we tested associations with (III) previous MDD-episodes, (IV) prospective recurrence, and (V) effects of cognitive therapy. METHODS: At study-entry, we cross-sectionally compared morning and evening salivary DHEAS and molar cortisol/DHEAS-ratio of 187 remitted recurrent MDD-patients with 72 matched controls. Subsequently, patients participated in an 8-week randomized controlled cognitive therapy trial. We repeated salivary measures after 3 months and 2 years. We measured clinical symptoms during a 10-year follow-up. RESULTS: Remitted patients showed steeper diurnal DHEAS-decline (p<.005) and a flatter diurnal profile of cortisol/DHEAS-ratio (p<.001) than controls. We found no state-effect in DHEAS or cortisol/DHEAS-ratio throughout follow-up and no association with number of previous episodes. Higher morning cortisol/DHEAS-ratio predicted shorter time till recurrence over the 10-year follow-up in interaction with the effects of cognitive therapy (p<.05). Finally, cognitive therapy did not influence DHEAS or cortisol/DHEAS-ratio. CONCLUSIONS: Diurnal profiles of DHEAS and cortisol/DHEAS-ratio remain equally altered in between depressive episodes, and may predict future recurrence. This suggests they represent an endophenotypic vulnerability trait rather than a state-effect, which provides a new road to understand recurrent depression and its prevention. TRIAL REGISTRATION: www.isrctn.com/ISRCTN68246470.
Authors: Fiona Ge; Paula R Pietromonaco; Casey J DeBuse; Sally I Powers; Douglas A Granger Journal: Psychoneuroendocrinology Date: 2016-07-22 Impact factor: 4.905
Authors: Christina M Hough; Daniel Lindqvist; Elissa S Epel; Molly St Denis; Victor I Reus; F Saverio Bersani; Rebecca Rosser; Laura Mahan; Heather M Burke; Owen M Wolkowitz; Synthia H Mellon Journal: Psychoneuroendocrinology Date: 2016-12-05 Impact factor: 4.905
Authors: K Mareckova; L Holsen; R Admon; S Whitfield-Gabrieli; L J Seidman; S L Buka; A Klibanski; J M Goldstein Journal: J Affect Disord Date: 2017-06-28 Impact factor: 4.839
Authors: Rosemary Basson; Julia I O'Loughlin; Joanne Weinberg; Allan H Young; Tamara Bodnar; Lori A Brotto Journal: Psychoneuroendocrinology Date: 2019-03-08 Impact factor: 4.905
Authors: Olivia R Orta; Tianyi Huang; Laura D Kubzansky; Kathryn L Terry; Brent A Coull; Michelle A Williams; Shelley S Tworoger Journal: Psychoneuroendocrinology Date: 2019-11-14 Impact factor: 4.905
Authors: Rowen O Jin; Sara Mason; Synthia H Mellon; Elissa S Epel; Victor I Reus; Laura Mahan; Rebecca L Rosser; Christina M Hough; Heather M Burke; Susanne G Mueller; Owen M Wolkowitz Journal: Psychoneuroendocrinology Date: 2016-06-28 Impact factor: 4.905
Authors: Luis H Souza-Teodoro; Cesar de Oliveira; Kate Walters; Livia A Carvalho Journal: Psychoneuroendocrinology Date: 2015-11-12 Impact factor: 4.905